Conditions: Depressive Disorder, Major Metabolic Syndrome X
Keywords: Depressive Disorder, Major Metabolic Syndrome X pioglitazone
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 23
Healthy volunteers: no

Brief summary:
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid Metabolic Syndrome (METSYN).

Detailed description:

Arms:
arm 1: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.

Interventions: intervention 1: Pioglitazone
Intervention descriptions: intervention 1: An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.

Protocol document: